title: Effects of eicosapentaenoic acid on biochemical failure after radical prostatectomy for prostate cancer.
abstract: OBJECTIVE
  To study the effects of eicosapentaenoic acid (EPA) on prostate-specific antigen (PSA) failure in prostate cancer patients who underwent prostatectomy.
  
  
  METHODS
  Sixty-two prostate cancer patients whose PSA levels were less than 0.2 ng/ml 3 months after surgery were randomized to either an EPA group (n=32) or a control group (n=30). EPA (2.4 g/day) was administered in the EPA group for 2 years. PSA was measured every two months.
  
  
  RESULTS
  The EPA concentration increased but the docosahexaenoic acid concentration decreased significantly (P<0.001) in erythrocytes. The PSA recurrence rates during a mean follow-up of 53.8 months were not different between the two groups (p=0.16).
  
  
  CONCLUSIONS
  A longer and/or larger intervention or docosahexaenoic acid supplementation might be necessary to identify significant preventive effects of mega-3 polyunsaturated fatty acids on PSA recurrence.
authors.affiliation: Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan. ehigashi@ks.kyorin-u.ac.jp
authors.forename: Eiji
authors.initials: E
authors.lastname: Higashihara
authors.forename: Miho
authors.initials: M
authors.lastname: Itomura
authors.forename: Toshiro
authors.initials: T
authors.lastname: Terachi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Matsuda
authors.forename: Mutushi
authors.initials: M
authors.lastname: Kawakita
authors.forename: Shuji
authors.initials: S
authors.lastname: Kameyama
authors.forename: Hideki
authors.initials: H
authors.lastname: Fuse
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Chiba
authors.forename: Tomohito
authors.initials: T
authors.lastname: Hamazaki
authors.forename: Takatsugu
authors.initials: T
authors.lastname: Okegawa
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Tokunaga
authors.forename: Takashi
authors.initials: T
authors.lastname: Murota
authors.forename: Gen
authors.initials: G
authors.lastname: Kawa
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Furuya
authors.forename: Takuya
authors.initials: T
authors.lastname: Akashi
authors.forename: Kei
authors.initials: K
authors.lastname: Hamazaki
authors.forename: Hideho
authors.initials: H
authors.lastname: Takada
mesh_terms: D000368:Aged; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000601:surgery*; D055502:Secondary Prevention; D013739:Testosterone / Q000378:metabolism; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D005231:Fatty Acids, Unsaturated; D013739:Testosterone; D007986:Luteinizing Hormone; D015118:Eicosapentaenoic Acid; D017430:Prostate-Specific Antigen